Sunday, December 1, 2019

Sun Pharma to defend antitrust claims over delayed entry of 3 generic drugs in US

Sun Pharma to defend antitrust claims over delayed entry of 3 generic drugs in US Sun Pharma said the litigation had already been disclosed in the company#39;s FY19 annual report.

from Moneycontrol Business News https://ift.tt/2ODfudW

No comments:

Post a Comment

FII exodus deepens in 2026 at Rs 1.75 lakh crore as April outflows swell to Rs 43,967 crore; FOMC next trigger

Foreign institutional investors offloaded Indian equities worth Rs 17,140 crore last week, extending April's outflows to Rs 43,967 crore...